A detailed history of Deep Track Capital, LP transactions in Vigil Neuroscience, Inc. stock. As of the latest transaction made, Deep Track Capital, LP holds 1,553,996 shares of VIGL stock, worth $4.69 Million. This represents 0.19% of its overall portfolio holdings.

Number of Shares
1,553,996
Previous 597,215 160.21%
Holding current value
$4.69 Million
Previous $2.39 Million 121.23%
% of portfolio
0.19%
Previous 0.08%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.92 - $4.65 $2.79 Million - $4.45 Million
956,781 Added 160.21%
1,553,996 $5.28 Million
Q2 2024

Aug 14, 2024

SELL
$2.51 - $4.66 $2.5 Million - $4.65 Million
-997,716 Reduced 62.56%
597,215 $2.39 Million
Q4 2023

Feb 14, 2024

SELL
$2.97 - $8.6 $511,434 - $1.48 Million
-172,200 Reduced 9.74%
1,594,931 $5.39 Million
Q3 2023

Nov 14, 2023

SELL
$4.8 - $9.92 $30,134 - $62,277
-6,278 Reduced 0.35%
1,767,131 $9.52 Million
Q2 2023

Aug 14, 2023

SELL
$8.11 - $10.54 $2.04 Million - $2.65 Million
-251,728 Reduced 12.43%
1,773,409 $16.7 Million
Q1 2023

May 15, 2023

SELL
$8.77 - $12.7 $693,154 - $1 Million
-79,037 Reduced 3.76%
2,025,137 $19.8 Million
Q4 2022

Feb 14, 2023

SELL
$8.74 - $15.99 $2.26 Million - $4.14 Million
-259,014 Reduced 10.96%
2,104,174 $26.3 Million
Q3 2022

Nov 14, 2022

BUY
$2.37 - $9.61 $4.87 Million - $19.7 Million
2,054,795 Added 666.29%
2,363,188 $21.5 Million
Q2 2022

Aug 12, 2022

SELL
$2.23 - $7.81 $180,068 - $630,641
-80,748 Reduced 20.75%
308,393 $796,000
Q1 2022

May 16, 2022

BUY
$7.03 - $17.29 $2.74 Million - $6.73 Million
389,141 New
389,141 $2.74 Million

Others Institutions Holding VIGL

About Vigil Neuroscience, Inc.


  • Ticker VIGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,268,600
  • Market Cap $85.4M
  • Description
  • Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed...
More about VIGL
Track This Portfolio

Track Deep Track Capital, LP Portfolio

Follow Deep Track Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deep Track Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Deep Track Capital, LP with notifications on news.